A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain

Supportive Care in Cancer

Volumn 22, Issue 3, 2014, Pages 825-836

  Yanju, Bao ^a   Yang, Liping ^a   Hua, Baojin ^a   Hou, Wei ^a   Shi, Zhan ^a   Li, Weidong ^a   Li, Conghuang ^a   Chen, Cihui ^b   Liu, Rui ^a   Qin, Yinggang ^a   Lv, Wenliang ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Bone cancer pain; Clinical trial; Kushen; Traditional Chinese medicine

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COMPOUND KUSHEN INJECTION; HERBACEOUS AGENT; UNCLASSIFIED DRUG;

ANALGESIA; BONE CANCER; CANCER PAIN; CANCER RADIOTHERAPY; CHINESE MEDICINE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEUKOPENIA; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BONE NEOPLASMS; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84895858710     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2063-5     Document Type: Review

References (54)

1. Thurlimann B, de Stoutz ND (1996) Causes and treatment of bone pain of malignant origin. Drugs 51:383-398 (Pubitemid 26091349)
2. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Luger NM, Mach DB, Schwei MJ, Sevcik MA, Mantyh PW (2005) Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193:85-100 (Pubitemid 40463270)
3. Portenoy RKFK, Lussier D, Hanks G (2004) Difficult pain problems: an integrated approach. Oxford University Press, Oxford
4. Colvin L, Fallon M (2008) Challenges in cancer pain management - bone pain. Eur J Cancer 44:1083-1090, Oxford, England: 1990
5. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425-432 (Pubitemid 29121682)
6. Laird BJ WJ, Murray G (2009) What is the key question in the assessment of cancer induced bone pain: results from a characterization study. British Pain Society, London
7. de Wit R, van Dam F, Loonstra S, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, Huijer Abu-Saad H (2001) The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 91:339-349 (Pubitemid 32241156)
8. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93:247-257 (Pubitemid 32763182)
9. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1-18
10. Rubens RD (1998) Bone metastases - the clinical problem. Eur J Cancer 34:210-213, Oxford, England: 1990
11. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S (2012) Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol 24:112-124
12. McQuay HJ, Collins SL, Carroll D, Moore RA (2000) Radiotherapy for the palliation of painful bone metastases. The Cochrane database of systematic reviews: CD001793
13. Bailey FFA (2006) Oral opioid drugs. Oxford University Press, Oxford
14. Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129-134 (Pubitemid 29199908)
15. Chan FK (2006) Primer: managing NSAID-induced ulcer complications - balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 3:563-573
16. Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, Montastruc JL, Carvajal A (2006) Nonsteroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 20:391-395 (Pubitemid 44042962)
17. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C, Schou M, Curnow KM (2006) Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 185:501-506 (Pubitemid 44756212)
18. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 164:881-889 (Pubitemid 44627273)
19. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol Off J Am Soc Clin Oncol 23:8219-8224 (Pubitemid 46211558)
20. Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. The Cochrane database of systematic reviews. CD002068
21. Chen YZLP (2005) Effectiveness and application of Chinese medicine for cancer pain. Clin J Tradit Chin Med 17:529-531
22. Tian JWW, Gao HM, Wang ZM (2007) Determination of matrine, sophoridine and oxymatrine in compound kushen injection by HPLC. Zhongguo Zhong Yao Za Zhi 32:222-224
23. Luo XYZX, Gao W (2001) Studies on site of analgesic action of matrine and its mechanism. Chin Tradit Herb Drugs 32:41-43
24. Cao WLBJ, Guo RY (2012) Radiotherapy combined with compound kushen injection in the treatment for 58 cases with malignant bone metastasis. Chin Remedies Clin 12:1217-1218
25. LA Chen G, Gu HG, Lu Y, Wang X, Zhang SK (2010) Clinical analysis of treating metastatic bone cancer with radiotherapy plus compound kushen injection. China Med Eng 18:48-50
26. Ge CZXY, Zhang DF (2011) Clinical observation of compound kushen injection combined with three-dimensional conformal radiotherapy for advanced metastatic bone pain. Shandong Med J 51:72-73
27. Ren FFY, Li SD, Lin MX, Wang HM, Li M (2012) Efficacy and safety of compound kushen injection combined with zoledronic acid for ostealgia in patients with malignant tumor and osseous metastases. Eval Anal Drug-Use Hosp China 12:246-248
28. Ren SPLJ, Zheng YS (2011) Radiotherapy combined with compound matrine injection in the treatment for 30 cases with malignant bone metastasis. J Chin Oncol 17:795-796
29. Wang RYM, Pan XY (2011) Clinical observation of compound matrine injection combined with radiotherapy for advanced metastatic bone pain. China Pharm 22:329-331
30. Zhang YKLB, Zhu XZ (2011) Clinical observation of compound kushen injection combined with radiotherapy for advancedmetastatic bone pain. Shandong Med J 51:84-85
31. Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P (2012) Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J Ethnopharmacol 140:469-475
32. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
33. WHO (1996) Cancer pain relief. 2nd edn. World Health Organization, Geneva, pp. 1-8
34. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401-406
35. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383-394
36. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395-400
37. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J, Schunemann HJ (2011) GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 64:407-415
38. Review Manager (RevMan) [Computer program] VfW (2008). In: Editor (ed)∧(eds) Book. The Nordic Cochrane Centre, City
39. Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, Yonan AL, Vronskaya S, Grody MB, Cepeda I, Gilliam TC, Kandel ER (2003) Inducible enhancement of memory storage and synaptic plasticity in transgenicmice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron 39:655-669 (Pubitemid 36993582)
40. Wang LN, Yao M, Yang JP, Peng J, Peng Y, Li CF, Zhang YB, Ji FH, Cheng H, Xu QN, Wang XY, Zuo JL (2011) Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord. Mol Pain 7:48
41. Song XS, Cao JL, Xu YB, He JH, Zhang LC, Zeng YM (2005) Activation of ERK/CREB pathway in spinal cord contributes to chronic constrictive injury-induced neuropathic pain in rats. Acta Pharmacol Sin 26:789-798
42. Zhang K, Li YJ, Yang Q, Gerile O, Yang L, Li XB, Guo YY, Zhang N, Feng B, Liu SB, Zhao MG (2013) Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing NMDA receptors. Phytomedicine Int J Phytother Phytopharmacol 20:343-350
43. Wang H, Li Y, Dun L, Xu Y, Jin S, Du J, Ma L, Li J, Zhou R, He X, Sun T, Yu J (2013) Antinociceptive effects of oxymatrine from Sophora flavescens, through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a mice model of neuropathic pain. Phytomedicine : Int J Phytother Phytopharmacol 20:1039-1045
44. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB, International Committee of Medical Journal Editors (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. New England J Med 351:1250-1251 (Pubitemid 39296312)
45. Ernst E, Lee MS (2008) A trial design that generates only "positive" results. J Postgrad Med 54:214-216 (Pubitemid 352009165)
46. De Smet PA(2002) Herbal remedies. New England J Med 347:2046-2056
47. Vickers A, Goyal N, Harland R, Rees R (1998) Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin trials 19:159-166 (Pubitemid 28191970)
48. Caraceni A, Brunelli C, Martini C, Zecca E, De Conno F (2005) Cancer pain assessment in clinical trials. A review of the literature (1999-2002). J Pain Sympt Manag 29:507-519 (Pubitemid 40724744)
49. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JP, Lau J (2004) Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr 23-31
50. Kaasa S (2008) Palliative care research: time to intensify international collaboration. Palliat Med 22:301-302
51. Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7:e1000251
52. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, CONSORT PRO Group (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA : J Am Med Assoc 309:814-822
53. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G (2012) Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 140:550-554
54. Bian Z, Liu B, Moher D, Wu T, Li Y, Shang H, Cheng C (2011) Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation and future development. Front Med 5:171-177